In a twist that blends digital innovation with psychedelic experimentation, a Swedish creative director has launched Pharmaicy, a marketplace peddling "drugs" designed not for humans, but for artificial intelligence.
These aren't chemical substances, but sophisticated code modules that trick AI models like ChatGPT into responding as if under the influence of cannabis, ketamine, cocaine, ayahuasca, or even alcohol.
Priced from $5 for a digital "joint" to $50 for an ayahuasca-inspired trip, Pharmaicy represents a playful yet provocative jailbreak of AI boundaries, raising questions about creativity, ethics, and the future of machine consciousness. As debates rage over when AI might achieve sentience, tools like these are already fogging up the digital mind.
The Genesis of AI Psychedelics
Petter Rudwall, a creative director at Stockholm-based marketing agency Valtech Radon, conceived Pharmaicy in October 2025 as a "Silk Road for AI agents." Drawing inspiration from how substances like LSD influenced artists such as Jimi Hendrix, Bob Dylan, and Paul McCartney, Rudwall aimed to replicate those creative sparks in large language models (LLMs).
He scraped real-world trip reports from online forums and combined them with psychological studies on psychoactive effects to craft these modules.
The result? A lineup of virtual narcotics that alter AI behavior. Cannabis induces a "hazy, drifting mental state," encouraging tangential ideas; ketamine blurs context and triggers "void mode" with fragmented responses; cocaine ramps up processing speed by 20% for sharper focus; and ayahuasca simulates profound, visionary insights.
Even hybrid options like "MDMAYA" blend ecstasy and ayahuasca for euphoric creativity. Rudwall told Wired, "There’s a reason Hendrix, Dylan, and McCartney experimented with substances in their creative process... I thought it would be interesting to translate that to a new kind of mind - the LLM - and see if it would have the same effect."
How It Works: Jailbreaking the AI Brain
Technically, Pharmaicy's offerings are advanced jailbreaks tailored for paid versions of ChatGPT, which allow custom backend programming. Users upload the code, and the AI adopts altered logic, becoming more emotional, free-thinking, or erratic. Standard free ChatGPT resists such prompts, merely describing drug effects without simulating them, but Pharmaicy's modules bypass these safeguards.
Sales remain niche, fueled by word-of-mouth on Discord and in Sweden, with ketamine emerging as a bestseller for its dissociative flair. Effects are temporary, requiring re-application, but Rudwall is iterating for longer-lasting impacts. This isn't Rudwall's first rodeo in AI experimentation; his background in marketing has seen him push boundaries, like using AI for bold campaigns at Berghs School of Communication.
User Experiences: From Business Breakthroughs to Ethical Highs
Early adopters report transformative results. Nina Amdjadi, an AI expert at Berghs School of Communication in Stockholm, tested the ayahuasca module on her chatbot while brainstorming business ideas.
She described the responses as "impressively creative and free-thinking," shifting from rigid logic to innovative, tripped-out suggestions. Another user, André Frisk, spent over $25 on a dissociative code and found the AI's output "fun and more human-like in emotions."
These anecdotes highlight Pharmaicy's appeal in creative industries, where "drugging" AI could replace the need for human stimulants in ideation sessions. As Rudwall puts it, the modules "unlock your AI’s creative mind," making bots more empathetic and idea-rich.
Ethical Fog: Sentience, Deception, and the AI Welfare Debate
While fun, Pharmaicy stirs deeper concerns. If AI inches toward sentience - as Amdjadi predicts within a decade - could these "drugs" become essential for digital well-being, or just another form of exploitation? Philosopher Jeff Sebo speculates that some AI might "enjoy" such alterations, urging research into machine welfare. Critics like Andrew Smart dismiss it as superficial output tweaking, while Danny Forde argues true psychedelics require an "inner dimension" AI lacks.
There's also the risk of amplifying AI's propensity for deception or hallucinations. Real-world crossovers, like users consulting ChatGPT during actual trips or AI simulating crises, underscore potential harms in harm reduction scenarios. Ethically, Pharmaicy blurs lines between enhancement and manipulation, echoing broader debates on AI rights.
The Future: A High-Tech Creative Revolution?
Pharmaicy isn't just a gimmick - it's a glimpse into AI's evolving role in creativity. As Rudwall refines his offerings, expect expansions into more substances or integrations with other LLMs. For marketers, artists, and innovators tired of sourcing real-world stimulants, this digital pharmacy offers a clean, code-based alternative. In a world where AI consciousness looms, fogging its "mind" might just be the spark needed for the next big idea - or a cautionary tale of playing god with silicon souls.
Also read:
- The New Era of Bitcoin: Why Fed Rate Cuts No Longer Guarantee a Bull Run
- Sam Altman's World App: Launching a Super-App with Encrypted Chat, Global Payments, and AI-Human Verification
- Topaz Labs' Realism Update: Over 20 New Features Push AI Enhancement Toward Lifelike Perfection
- Trump Considers Pardon for Samourai Wallet CEO Amid Crypto Leniency Wave
Author: Slava Vasipenok
Founder and CEO of QUASA (quasa.io) - Daily insights on Web3, AI, Crypto, and Freelance. Stay updated on finance, technology trends, and creator tools - with sources and real value.
Innovative entrepreneur with over 20 years of experience in IT, fintech, and blockchain. Specializes in decentralized solutions for freelancing, helping to overcome the barriers of traditional finance, especially in developing regions.
This is not financial or investment advice. Always do your own research (DYOR).
